Guelar A, Knobel H. Guida alle interazioni degli antiretrovirali. Edizione Italiana 2007 Momento Medico S.r.l.
Gruber VA, McCance-Katz EF. Methadone, Buprenorphine, and Street Drug Interactions with Antiretroviral Medications. Curr HIV/AIDS Rep 2010; 7: 152-60
Antoniou T, Tseng AL. Interaction Between recreational Drugs and Antiretroviral Agents. The Annals of Pharmacotherapy 2002; 36: 1598-1613
Scholler-Gyure M, van den Brink W, Kakuda TN, et al. Pharmacokinetic and pharmacodynamic study of concomitant administration of metadone and TMC125 in HIV-negative volunteers. J Clin Pharmacol 2008, 48: 322-9
Tony Antoniou and Alice lin-in Tseng. Interactions between reacretional drugs and antiretroviral agents. Ann Pharmacother 2002; 36: 1598-613
Kreth K, Kovar K, Schwab M, et al. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related drugs. Biochem Pharmacol 2000; 15: 1563-71
Kosel BW, Aweeka FT, Benowitz NL, et al. The effects of cannabinoids on th pharmacokinetics of indinavir and nelfinavir. AIDS 2002, 16: 534-50.
Abrams DI, Hilton JF, Leiser RJ, et al. Short-term effects of cannabinoids in patients with HIV-1 infection: A randomized, placebo-controlled clinical trial. Ann Int Med 2003; 139: 258-66
Lopez P, Velez R, Rivera V. Characteristics of P-glycoprotein (Pgp) upregulated in chronic cocaine users and HIV infected persons. Retrovirology 2005, 2 (Suppl 1): 142
Pichini S, Marchei E, Palmi I, et al. Smart Drugs. Osservatorio Fumo, Alcol e Droga, Dipartimento del Farmaco, Istituto Superiore di Sanità. Seconda Edizione 2008.
Antoniou T, Tseng AL, Van Heeswijk RP, et al. Steady-state pharmacokinetics and tolerability of indinavir-lopinavir/ricombination therapy in antiretroviral-experienced patients. Ther Drug Monit. 2005; 27: 779-81.